NKGN vs. ATYR, VXRT, CLLS, CYBN, IMAB, KPTI, CTMX, ORMP, YS, and ACRS
Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include Atyr PHARMA (ATYR), Vaxart (VXRT), Cellectis (CLLS), Cybin (CYBN), I-Mab (IMAB), Karyopharm Therapeutics (KPTI), CytomX Therapeutics (CTMX), Oramed Pharmaceuticals (ORMP), YS Biopharma (YS), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.
Atyr PHARMA (NASDAQ:ATYR) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking.
Atyr PHARMA has higher revenue and earnings than NKGen Biotech.
Atyr PHARMA presently has a consensus target price of $35.00, suggesting a potential upside of 1,476.58%. Given NKGen Biotech's higher probable upside, equities analysts clearly believe Atyr PHARMA is more favorable than NKGen Biotech.
Atyr PHARMA's return on equity of 0.00% beat NKGen Biotech's return on equity.
Atyr PHARMA received 1 more outperform votes than NKGen Biotech when rated by MarketBeat users.
Atyr PHARMA has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
61.7% of Atyr PHARMA shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 3.7% of Atyr PHARMA shares are owned by insiders. Comparatively, 20.0% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Atyr PHARMA had 6 more articles in the media than NKGen Biotech. MarketBeat recorded 8 mentions for Atyr PHARMA and 2 mentions for NKGen Biotech. NKGen Biotech's average media sentiment score of 1.36 beat Atyr PHARMA's score of 0.28 indicating that Atyr PHARMA is being referred to more favorably in the media.
Summary
Atyr PHARMA beats NKGen Biotech on 9 of the 13 factors compared between the two stocks.
Get NKGen Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NKGen Biotech Competitors List
Related Companies and Tools
